Ireland-based Mallinckrodt Public Limited Company focuses on developing treatments for autoimmune and rare diseases (including neurology, rheumatology, nephrology and pulmonology) as well as therapies for pain management.
The company develops, manufactures, markets and distributes both branded and specialty generic pharmaceuticals. The company reports in three segments: Specialty Brands, Specialty Generics and Nuclear Imaging. The company sold its contrast media and delivery systems business to Guerbet S.A. in Nov 2015.
Mallinckrodt acquired Ikaria Inc. in 2015 to strengthen its business in the hospital market. With the addition of Inomax to its portfolio, Mallinckrodt gained access to the market for neonatal critical care, which helped it to diversify its portfolio in the Specialty Brands segment.
The company also acquired Therakos Inc. in Sep 2015 to widen its presence from multimodal surgical pain management and critical care respiratory therapies in neonatal intensive care units to include innovative immunotherapy therapies. Moreover, in Feb 2016 the company acquired three commercial stage topical hemostasis drugs from The Medicines Company to strengthen its growing hospital portfolio.
However, the company sold its Nuclear Imaging business to IBA Molecular for $690 million.
Mallinckrodt has an excellent earnings track record with the company delivering positive earnings surprises in each of the last four quarters with a positive average earnings surprise of 8.72%. Estimate revisions for Mallinckrodt for fiscal 2017 have were up by a penny in the last thirty days.
Currently, Mallinckrodt has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mallinckrodt beat on earnings. Our consensus called for EPS of $1.63, and the company reported EPS of $1.68.
Revenue: Revenues also surpassed expectations. Mallinckrodt posted revenues of $810.9 million, compared to our consensus estimate of $787.5 million.
Key Stats: Revenue growth was primarily driven by volume growth of key branded drugs – Acthar, Inomax and Ofirmev. Specialty generics segment continue to be under pressure.
Check back later for our full write up on this Mallinckrodt earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Ireland-based Mallinckrodt Public Limited Company focuses on developing treatments for autoimmune and rare diseases (including neurology, rheumatology, nephrology and pulmonology) as well as therapies for pain management.
The company develops, manufactures, markets and distributes both branded and specialty generic pharmaceuticals. The company reports in three segments: Specialty Brands, Specialty Generics and Nuclear Imaging. The company sold its contrast media and delivery systems business to Guerbet S.A. in Nov 2015.
Mallinckrodt acquired Ikaria Inc. in 2015 to strengthen its business in the hospital market. With the addition of Inomax to its portfolio, Mallinckrodt gained access to the market for neonatal critical care, which helped it to diversify its portfolio in the Specialty Brands segment.
The company also acquired Therakos Inc. in Sep 2015 to widen its presence from multimodal surgical pain management and critical care respiratory therapies in neonatal intensive care units to include innovative immunotherapy therapies. Moreover, in Feb 2016 the company acquired three commercial stage topical hemostasis drugs from The Medicines Company to strengthen its growing hospital portfolio.
However, the company sold its Nuclear Imaging business to IBA Molecular for $690 million.
Mallinckrodt has an excellent earnings track record with the company delivering positive earnings surprises in each of the last four quarters with a positive average earnings surprise of 8.72%. Estimate revisions for Mallinckrodt for fiscal 2017 have were up by a penny in the last thirty days.
Currently, Mallinckrodt has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mallinckrodt beat on earnings. Our consensus called for EPS of $1.63, and the company reported EPS of $1.68.
Revenue: Revenues also surpassed expectations. Mallinckrodt posted revenues of $810.9 million, compared to our consensus estimate of $787.5 million.
Key Stats: Revenue growth was primarily driven by volume growth of key branded drugs – Acthar, Inomax and Ofirmev. Specialty generics segment continue to be under pressure.
Check back later for our full write up on this Mallinckrodt earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>